-
Catalyst Pharmaceuticals Press Release April 8, 2020
It is definitely a worrisome time as a rare disease patient. For some autoimmune patients, such those with lupus and severe arthritis, their go-to med, hydroxychloroquine, suddenly is highlighted as a potential life saver for those with COVID-19. A treatment that many LEMS patients depend upon, IVIG, is also found to be a potential life saving treatment. While it is hopeful and necessary to have potential treatments for COVID-19, it is scary to think of what patients who have already depended on these lifesaving treatments will do when the supply can’t meet the demand. Many of us, including myself, experienced what that deficit was like last year during the IVIG shortage.
Catalyst Pharmaceuticals’ press release continues to reassure LEMS patients on FIRDAPSE that this pandemic shouldn’t affect the supply. Catalyst is also continuing to serve the LEMS patient community and their providers through phone and web based applications. This is reassuring, especially when added stress in life can cause our disease to flare. I hope this one little piece of news calms some of your fears.
Stay safe and be well everyone.
-
2 Replies
-
Thanks for sharing!!
-
Catalyst continues to demonstrate why they are such a first class partner with all of us.
Log in to reply.